HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Omacor

a drug containing the n-3 fatty acids that corrects plasma lipid; antiarrhthymic
Also Known As:
Lovaza; P-OM3 adjunct; omega-3 ethyl ester 90
Networked: 59 relevant articles (6 outcomes, 25 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Byrne, Christopher D: 5 articles (01/2018 - 10/2014)
2. Clough, Geraldine F: 5 articles (01/2018 - 10/2014)
3. Scorletti, Eleonora: 5 articles (01/2018 - 10/2014)
4. Bhatia, Lokpal: 4 articles (03/2016 - 10/2014)
5. Calder, Philip C: 4 articles (03/2016 - 10/2014)
6. Elajami, Tarec K: 3 articles (07/2018 - 01/2016)
7. Welty, Francine K: 3 articles (07/2018 - 01/2016)
8. McCormick, Keith G: 3 articles (01/2016 - 10/2014)
9. Lip, Gregory Y H: 3 articles (01/2007 - 01/2006)
10. Alfaddagh, Abdulhamied: 2 articles (07/2018 - 07/2017)

Related Diseases

1. Hypertriglyceridemia
2. Inflammation (Inflammations)
01/01/2006 - "Three-month supplementation of Omacor at 1 g per day in post-MI patients is not associated with an improvement in the levels of peripheral indices of coagulation potential, endothelial function, platelet reactivity and inflammation."
03/01/2016 - "In a pre-specified sub-study of the WELCOME (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy) trial (NCT00760513), CIMT was measured using B-mode ultrasound while NAFLD severity was assessed by measuring liver fat percentage (magnetic resonance spectroscopy) and hepatic necro-inflammation (serum cytokeratin-18 (CK-18) concentration), at baseline and end of study. "
02/01/2011 - "A number of novel therapeutic agents have also been tested in db/db mice, including inhibitors of inflammation (chemokine receptor antagonists, anti-CCL2 RNA aptamer, anti-c-fms antibody); oxidative stress (oxykine, biliverdin); the renin-angiotensin-aldosterone system (aliskiren, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone); advanced glycation end products (AGE; pyridoxamine, alagebrium, soluble AGE receptor); angiogenesis (NM-3, anti-CXCL12 RNA aptamer, soluble Flt-1); lipid accumulation (statins, farnesoid X receptor agonists, Omacor); intracellular signaling pathways (PKC-β or JNK inhibitors); and fibrosis [transforming growth factor (TGF)-β antibody, TGF-βR kinase inhibitor, soluble betaglycan, SMP-534, CTGF-antisense oligonucleotide, mutant PAI-1, pirfenidone], which have identified potential therapeutic targets for clinical translation. "
3. Insulin Resistance
4. Infarction (Infarctions)
5. Glucose Intolerance

Related Drugs and Biologics

1. Omacor
2. Docosahexaenoic Acids
3. Eicosapentaenoic Acid
4. Biomarkers (Surrogate Marker)
5. Insulin (Novolin)
6. Glucose (Dextrose)
7. Dietary Fats (Dietary Fat)
8. eicosapentaenoic acid ethyl ester
9. Omega-3 Fatty Acids (Omega 3 Fatty Acids)
10. Fish Oils

Related Therapies and Procedures

1. Therapeutics
2. Secondary Prevention
3. Chemoprevention
4. Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
5. Investigational Therapies (Experimental Therapy)